Compare DELL & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | VRTX |
|---|---|---|
| Founded | 1984 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.7B | 115.7B |
| IPO Year | 2013 | 2006 |
| Metric | DELL | VRTX |
|---|---|---|
| Price | $147.81 | $486.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 27 |
| Target Price | $163.47 | ★ $526.79 |
| AVG Volume (30 Days) | ★ 7.9M | 1.3M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | 5.34 | ★ 15.32 |
| Revenue | ★ $95,567,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $12.23 | $11.10 |
| Revenue Next Year | $7.00 | $10.23 |
| P/E Ratio | ★ $28.57 | $31.74 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $66.25 | $362.50 |
| 52 Week High | $168.08 | $519.68 |
| Indicator | DELL | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 53.17 |
| Support Level | $112.28 | $432.09 |
| Resistance Level | $167.09 | $484.17 |
| Average True Range (ATR) | 5.82 | 13.39 |
| MACD | 3.95 | 0.56 |
| Stochastic Oscillator | 94.37 | 53.26 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.